ArticleTobacco induced diseases2025
Assessment of smoking cessation outcomes in patients with cardiovascular disease: A retrospective cohort study from Türkiye.
Article in Tobacco induced diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Characteristics and Factors Associated with One-Year Smoking Cessation Among Smokers with COPD: A Subgroup Analysis of a Multicentre Randomised Trial.International journal of chronic obstructive pulmonary disease · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCardiovascular disease (CVD) is a major preventable cause of mortality, and smoking cessation significantly reduces the risk of recurrent cardiovascular events. However, many patients continue smoking despite their CVD diagnosis. This study aims to evaluate the impact of CVD and associated factors on smoking cessation success in patients who attempted to quit smoking at least one year ago.
methodsThis retrospective cohort study included patients who applied to the Smoking Cessation Clinic (SCC) between 1 May 2022 and 30 April 2023. A total of 539 eligible patients were analyzed. Data on demographics, CVD status, Fagerström test for nicotine dependence score, treatment modality (bupropion, nicotine replacement therapy, behavioral counseling), and smoking cessation outcomes were collected from medical records and confirmed via telephone interviews. Smoking cessation success was defined as complete abstinence after one year.
resultsAmong the participants, 145 (26.9%) had a history of CVD. The overall self-reported smoking cessation success rate after one year was 16.7%, and 17.2% in the CVD group. Bupropion users had significantly higher treatment completion rates (p=0.015). Multivariable logistic regression analysis revealed that older age (AOR=1.03; 95% CI: 1.01-1.05), higher level of education (AOR=1.84; 95% CI: 1.03-3.26), lower nicotine dependence score (AOR=0.85; 95% CI: 0.77-0.94), and treatment completion (AOR=0.13, 95% CI: 0.07-0.23) were significantly associated with smoking cessation success in the total sample. Among patients with CVD, older age (AOR=1.06; 95% CI: 1.01-1.12) and treatment completion (AOR=0.15; 95% CI: 0.05-0.43) were also associated with higher cessation success. Patients with CVD were more likely to receive non-pharmacological interventions, and behavioral counseling alone showed the highest success rate (25.0%).
conclusionsOlder age and treatment adherence were significantly associated with smoking cessation success, yet overall cessation rates remained low. A CVD diagnosis alone did not significantly enhance success, highlighting the need for tailored behavioral support and structured follow-up. Optimizing cessation programs with individualized interventions may improve outcomes, particularly in high-risk CVD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.